PRAMOSONE
Clinical safety rating: caution
Comprehensive clinical and safety monograph for PRAMOSONE (PRAMOSONE).
Pramoxine acts as a local anesthetic by reversibly blocking sodium channels in nerve cell membranes, reducing neuronal membrane permeability to sodium ions and thereby inhibiting the initiation and conduction of nerve impulses. Hydrocortisone is a corticosteroid that suppresses inflammation by inhibiting phospholipase A2, reducing prostaglandin and leukotriene synthesis, and modulating immune cell activity.
| Metabolism | Pramoxine: Primarily metabolized in the liver via oxidative deamination and conjugation; Hydrocortisone: Primarily hepatic via CYP3A4 to inactive metabolites such as tetrahydrocortisone and 17-oxosteroids. |
| Excretion | Renal: 60-70% as unchanged drug; biliary/fecal: 20-30% as metabolites and parent compound. |
| Half-life | Terminal half-life: 3-4 hours for pramoxine; clinical context: short duration requiring frequent application; in hepatic impairment, may be prolonged. |
| Protein binding | Approximately 70-80% bound to albumin and alpha-1-acid glycoprotein. |
| Volume of Distribution | Vd: 1.5-2.5 L/kg, indicating extensive tissue distribution. |
| Bioavailability | Topical: minimal systemic absorption (<5%); rectal: <10% due to local metabolism and first-pass effect. |
| Onset of Action | Topical: within 1-2 minutes; rectal: within 5 minutes. |
| Duration of Action | Topical: 2-4 hours; rectal: 3-6 hours; note: duration may be shorter in inflamed mucosa. |
| Molecular Weight | Pramoxine HCl: 329.86 Da; Hydrocortisone: 362.46 Da. The combination product contains both; note that Pramosone is a combination drug. |
Topical: Apply thin layer to affected area 3-4 times daily. Rectal: Insert 1 suppository (2% pramoxine HCl and 1% hydrocortisone acetate) rectally twice daily (morning and evening).
| Dosage form | LOTION |
| Renal impairment | No dosage adjustment required for topical or rectal use. |
| Liver impairment | No dosage adjustment required for topical or rectal use. |
| Pediatric use | Safety and efficacy not established; use only if clearly needed. |
| Geriatric use | Use with caution due to increased risk of skin atrophy and systemic absorption; apply sparingly to limited areas. |
| 1st trimester | Pramoxine and hydrocortisone combination (Pramosone) has no adequate studies in pregnant women. Animal reproduction studies are lacking. Systemic corticosteroids are known to cause fetal harm in first trimester; however, topical absorption of hydrocortisone is minimal. Use only if clearly needed. |
| 2nd trimester | Same as first trimester. Topical corticosteroids in the second trimester should be used with caution due to risk of fetal growth restriction with prolonged use of potent corticosteroids; Pramosone contains low-potency hydrocortisone, but minimal systemic absorption occurs. |
| 3rd trimester | Topical corticosteroids in third trimester may be associated with low birth weight if used extensively. However, Pramosone contains low-potency hydrocortisone and pramoxine; minimal systemic absorption is expected. Use only if potential benefit outweighs risk. |
Clinical note
Comprehensive clinical and safety monograph for PRAMOSONE (PRAMOSONE).
| Placental transfer | Hydrocortisone undergoes placental transfer, but systemic absorption after topical application of low-potency hydrocortisone is minimal (less than 1% of applied dose). Pramoxine is a local anesthetic; no data on placental transfer in humans, but likely minimal due to low systemic absorption. |
■ FDA Black Box Warning
None.
| Serious Effects |
Hypersensitivity to pramoxine, hydrocortisone, or any component of the formulationAllergic skin reactions from corticosteroidsKnown systemic fungal or viral infections at the site of application (e.g., herpes simplex, varicella)Perioral dermatitisRosaceaPregnancy: not recommended for extensive use during pregnancy (especially prolonged or large areas)
| Precautions | Do not exceed recommended dosage or duration of use. Avoid contact with eyes. In case of rectal bleeding or persistent symptoms, discontinue use and consult a physician. Use with caution in patients with rectal mucositis or fecal impaction. Prolonged use of corticosteroids may lead to systemic absorption and adrenal suppression or skin atrophy. |
| Food/Dietary | No clinically significant food interactions. Topical application minimizes systemic absorption. |
Loading safety data…
| Breastfeeding | Pramoxine and hydrocortisone are excreted in breast milk in small amounts after topical application. The combination is considered compatible with breastfeeding when used on small areas and for short durations. Avoid application to the breast or nipple area to minimize infant ingestion. If applied to large areas or for prolonged periods, monitor infant for signs of adrenal suppression or local irritation. |
| Lactation Rating | L2 (Safer), compatible with breastfeeding with precautions. |
| Teratogenic Risk | Pramosome (pramoxine 1% and hydrocortisone 1%) is a topical combination. No well-controlled studies in pregnant women. Animal reproduction studies have not been conducted. Topical corticosteroids, in general, have been associated with low birth weight and cleft palate after systemic absorption at high doses. However, topical application minimizes systemic exposure. Risk to fetus cannot be ruled out; use only if clearly needed and guided by clinical assessment. Trimester-specific risks are not established. |
| Fetal Monitoring | No specific monitoring required for topical use. Monitor for signs of HPA axis suppression with prolonged use (especially if large areas or occlusive dressings are used). No fetal monitoring indicated. |
| Fertility Effects | No known effects on fertility. Topical corticosteroids and anesthetics have not been shown to impair reproductive function in humans. |
| Clinical Pearls | PRAMOSONE is a fixed-dose combination of pramoxine (a topical anesthetic) and hydrocortisone (a topical corticosteroid). It is used for relief of itching, redness, and swelling associated with anorectal disorders. Pramoxine provides rapid but short-lived anesthesia, while hydrocortisone reduces inflammation. Avoid prolonged use (>7 days) to prevent skin atrophy, striae, and secondary infection. Do not apply to infected areas without appropriate antimicrobial therapy. |
| Patient Advice | Apply a small amount to the affected area no more than 3 to 4 times daily. · Do not use for more than 7 days unless directed by your doctor. · Avoid contact with eyes. · Stop use and consult your doctor if irritation persists or worsens. · Do not use on broken or infected skin. |